Besides emphasizing intrathecal IgA as a marker for active MS, this research underscores the role of the gut–brain axis in CNS inflammation and gut-associated IgA+ B cells as targets for future treatment approaches. This evidence concerns the gene CD79A and myeloid sarcoma.